MedTrace Logo

To Study the Effect of Vytorin on Intracellular Lipid and Inflammation in Obese Subjects

NCT01420328 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-04-17

Study results available
· View outcomes & findings →

Summary

This study focuses on the use of Vytorin to study inflammatory markers in subjects with normal cholesterol.

Conditions

Interventions

DRUG

Vytorin

Simvastatin 40 mg and Ezetimibe 10 mg daily combination pill (Vytorin) for 6 weeks

DRUG

Placebo

Placebo treatment for 6 weeks

Sponsors & Collaborators

  • Kaleida Health

    collaborator OTHER

  • University at Buffalo

    lead OTHER

Principal Investigators

  • Paresh Dandona, MD · University at Buffalo, NY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-05-01
Primary Completion
2015-07-01
Completion
2016-07-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01420328 on ClinicalTrials.gov